The current state of Clinical Mycology in Eastern and South-Eastern Europe

Cândida Driemeyer; Diego R. Falci; Martin Hoenigl; Oliver A. Cornely; Arunaloke Chakrabarti; Jean Pierre Gangneux; Esther Segal; Marika Jürna-Ellam; Tadeja Matos; Jacques F. Meis; John R. Perfect; Valentina Arsic Arsenijevic; Mihai Mares; Daniela Elena Serban; Alessandro C. Pasqualotto

doi:10.1093/mmy/myac017

The current state of Clinical Mycology in Eastern and South-Eastern Europe

Cândida Driemeyer, Diego R. Falci, Martin Hoenigl, Oliver A. Cornely, Arunaloke Chakrabarti, Jean Pierre Gangneux, Esther Segal, Marika Jürna-Ellam, Tadeja Matos, Jacques F. Meis, John R. Perfect, Valentina Arsic Arsenijevic, Mihai Mares, Daniela Elena Serban, Alessandro C. Pasqualotto^*

^*Corresponding author for this work

Clinical Microbiology and Immunology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

The ability of medical centers in Eastern and South-Eastern Europe to diagnose and treat fungal infections remains unknown. In order to investigate that, here we conducted a cross-sectional online survey, released at both The International Society for Human & Animal Mycology (ISHAM) and European Confederation of Medical Mycology (ECMM) websites. A total of 31 institutions responded to the questionnaire. Most centers (87.1%, n = 27) had access to Aspergillus spp. ELISA galactomannan testing as well as to Cryptococcus spp. antigen testing (83.9%, n = 26). Serological tests were mostly available for Aspergillus species (80.6%, n = 25); and most institutions reported access to mold-active antifungal drugs (83.9%; n = 26), but 5-flucytosine was available to only 29% (n = 9) of the participant centers. In conclusion, this study represents the first attempt to document the strengths and limitations of the Eastern and South-Eastern European region for diagnosing and treating fungal diseases. Lay Summary: Our article is about the availability of diagnostic and treatments tools related to fungal infections in the countries of Eastern and South-Eastern region. Surveys like these are important to understand the gaps and point towards the fungal infections as a global health issue.

Original language	English
Article number	myac017
Journal	Medical Mycology
Volume	60
Issue number	4
DOIs	https://doi.org/10.1093/mmy/myac017
State	Published - 1 Apr 2022

Keywords

Antifungal agents
Diagnosis
Fungal infection
Laboratory
Mycology

Access to Document

10.1093/mmy/myac017

Cite this

Driemeyer, C., Falci, D. R., Hoenigl, M., Cornely, O. A., Chakrabarti, A., Gangneux, J. P., Segal, E., Jürna-Ellam, M., Matos, T., Meis, J. F., Perfect, J. R., Arsenijevic, V. A., Mares, M., Serban, D. E., & Pasqualotto, A. C. (2022). The current state of Clinical Mycology in Eastern and South-Eastern Europe. Medical Mycology, 60(4), Article myac017. https://doi.org/10.1093/mmy/myac017

@article{db53210acaf94a99aeb3467ab5e5ce32,

title = "The current state of Clinical Mycology in Eastern and South-Eastern Europe",

abstract = "The ability of medical centers in Eastern and South-Eastern Europe to diagnose and treat fungal infections remains unknown. In order to investigate that, here we conducted a cross-sectional online survey, released at both The International Society for Human & Animal Mycology (ISHAM) and European Confederation of Medical Mycology (ECMM) websites. A total of 31 institutions responded to the questionnaire. Most centers (87.1%, n = 27) had access to Aspergillus spp. ELISA galactomannan testing as well as to Cryptococcus spp. antigen testing (83.9%, n = 26). Serological tests were mostly available for Aspergillus species (80.6%, n = 25); and most institutions reported access to mold-active antifungal drugs (83.9%; n = 26), but 5-flucytosine was available to only 29% (n = 9) of the participant centers. In conclusion, this study represents the first attempt to document the strengths and limitations of the Eastern and South-Eastern European region for diagnosing and treating fungal diseases. Lay Summary: Our article is about the availability of diagnostic and treatments tools related to fungal infections in the countries of Eastern and South-Eastern region. Surveys like these are important to understand the gaps and point towards the fungal infections as a global health issue.",

keywords = "Antifungal agents, Diagnosis, Fungal infection, Laboratory, Mycology",

author = "C{\^a}ndida Driemeyer and Falci, {Diego R.} and Martin Hoenigl and Cornely, {Oliver A.} and Arunaloke Chakrabarti and Gangneux, {Jean Pierre} and Esther Segal and Marika J{\"u}rna-Ellam and Tadeja Matos and Meis, {Jacques F.} and Perfect, {John R.} and Arsenijevic, {Valentina Arsic} and Mihai Mares and Serban, {Daniela Elena} and Pasqualotto, {Alessandro C.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.",

year = "2022",

month = apr,

day = "1",

doi = "10.1093/mmy/myac017",

language = "אנגלית",

volume = "60",

journal = "Medical Mycology",

issn = "1369-3786",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - The current state of Clinical Mycology in Eastern and South-Eastern Europe

AU - Driemeyer, Cândida

AU - Falci, Diego R.

AU - Hoenigl, Martin

AU - Cornely, Oliver A.

AU - Chakrabarti, Arunaloke

AU - Gangneux, Jean Pierre

AU - Segal, Esther

AU - Jürna-Ellam, Marika

AU - Matos, Tadeja

AU - Meis, Jacques F.

AU - Perfect, John R.

AU - Arsenijevic, Valentina Arsic

AU - Mares, Mihai

AU - Serban, Daniela Elena

AU - Pasqualotto, Alessandro C.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - The ability of medical centers in Eastern and South-Eastern Europe to diagnose and treat fungal infections remains unknown. In order to investigate that, here we conducted a cross-sectional online survey, released at both The International Society for Human & Animal Mycology (ISHAM) and European Confederation of Medical Mycology (ECMM) websites. A total of 31 institutions responded to the questionnaire. Most centers (87.1%, n = 27) had access to Aspergillus spp. ELISA galactomannan testing as well as to Cryptococcus spp. antigen testing (83.9%, n = 26). Serological tests were mostly available for Aspergillus species (80.6%, n = 25); and most institutions reported access to mold-active antifungal drugs (83.9%; n = 26), but 5-flucytosine was available to only 29% (n = 9) of the participant centers. In conclusion, this study represents the first attempt to document the strengths and limitations of the Eastern and South-Eastern European region for diagnosing and treating fungal diseases. Lay Summary: Our article is about the availability of diagnostic and treatments tools related to fungal infections in the countries of Eastern and South-Eastern region. Surveys like these are important to understand the gaps and point towards the fungal infections as a global health issue.

AB - The ability of medical centers in Eastern and South-Eastern Europe to diagnose and treat fungal infections remains unknown. In order to investigate that, here we conducted a cross-sectional online survey, released at both The International Society for Human & Animal Mycology (ISHAM) and European Confederation of Medical Mycology (ECMM) websites. A total of 31 institutions responded to the questionnaire. Most centers (87.1%, n = 27) had access to Aspergillus spp. ELISA galactomannan testing as well as to Cryptococcus spp. antigen testing (83.9%, n = 26). Serological tests were mostly available for Aspergillus species (80.6%, n = 25); and most institutions reported access to mold-active antifungal drugs (83.9%; n = 26), but 5-flucytosine was available to only 29% (n = 9) of the participant centers. In conclusion, this study represents the first attempt to document the strengths and limitations of the Eastern and South-Eastern European region for diagnosing and treating fungal diseases. Lay Summary: Our article is about the availability of diagnostic and treatments tools related to fungal infections in the countries of Eastern and South-Eastern region. Surveys like these are important to understand the gaps and point towards the fungal infections as a global health issue.

KW - Antifungal agents

KW - Diagnosis

KW - Fungal infection

KW - Laboratory

KW - Mycology

UR - http://www.scopus.com/inward/record.url?scp=85128000478&partnerID=8YFLogxK

U2 - 10.1093/mmy/myac017

DO - 10.1093/mmy/myac017

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35195256

AN - SCOPUS:85128000478

SN - 1369-3786

VL - 60

JO - Medical Mycology

JF - Medical Mycology

IS - 4

M1 - myac017

ER -

The current state of Clinical Mycology in Eastern and South-Eastern Europe

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this